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Hematopoietic Cell Transplantation (HCT) from unrelated donors (UD) is a curative therapy for 
many hematologic malignancies. Donor-recipient allele-level matching at HLA-A, -B, -C, -DRB1 
(8/8) is widely accepted to provide best results in terms of overall survival (OS), non-relapse 
mortality (NRM) and graft-versus-host disease (GvHD)1. Genotypic matching for HLA-DPB1 
(DPB1) has been shown to hold limited, if any, impact on post-transplant OS, and would be 
challenging to adopt, due to the weak linkage disequilibrium between DPB1 and the remaining 
HLA class II loci. Therefore, more than 80% of 8/8-matched UD-HCT are currently DPB1-
mismatched1. A number of studies have demonstrated that biological models can be used to 
identify selected, permissive DPB1 mismatch combinations, associated with lower clinical risks 
compared to their high-risk, non-permissive, counterparts2-9. Five different biological models for the 
assignment of DPB1 permissiveness have been identified to date, of which three are based on 
functional T-Cell Epitopes (TCE), while the remaining two rely on a single nucleotide polymorphism 
(SNP) tag for expression levels. In particular, in the TCE3 model, DPB1 alleles are classified into 
three structural groups based on variation in the peptide antigen-binding domain, which leads to 
functionally similar or distinct behavior in terms of T-cell alloreactivity2-5. The TCE4 model is 
identical to TCE3, except for the assignment of DPB1*02 to a fourth, independent group4. Another 
derivative of TCE3 is the "delta functional distance" (ΔFD) model, in which a FD score is assigned 
to every DPB1 allele based on key polymorphic aminoacids involved in anti-DPB1 alloreactivity, 
and differences between the FDs of patient and donor alleles defines permissive and non-
permissive pairs, respectively6,7. The SNP models, in contrast, are based on high or low 
expression DPB1 alleles according to a SNP tag in the 3’ untranslated region, in which the 
rs9277534 A and G variant is associated with low and high DPB1 expression, respectively8-9. In the 
Expression model, this SNP tag is applied to all DPB1 alleles, while in the DP2/DP5 model, it is 
applied to 19 DPB1 alleles belonging either the DP2 or the DP5 evolutionary clade. Currently, 
TCE3 matching is proposed by stem cell donor registries in the US and Europe, because it is the 
only of these models to have been validated in independent cohorts. However, a comparative 
evaluation of the five different biological models for DPB1 permissiveness and their association 
with HCT outcome has not been undertaken so far. 
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Here, we have filled this gap by analysing the outcome of 422 patients with available 2nd field 
DPB1 typing transplanted from 8/8 HLA-A, -B, -C and -DRB1 allele matched UDs in 32 centers 
from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO), between 2012 and 2015. Of these, 
43 pairs had a mismatch at HLA-DQB1, and 382 had one or two DPB1 mismatches. The 
availability of DPB1 typing did not introduce significant biases, since clinical outcomes were similar 
for the 422 transplants under analysis and those (n=522) performed in the same time-period and 
for which DPB1 typing was not available (Supplemental Tables 1a and 1b). Patient, donor and 
transplant characteristics are shown in Table 1. Transplants were performed for hematologic 
malignancies, with mostly myeloablative conditioning and peripheral blood as stem cell source. 
GvHD prophylaxis included anti-T-lymphocytic globulin (ATG) in most cases. Permissive and non-
permissive mismatches were assigned by the IMGT webtool version 2.0 for TCE3, and manually 
for the other models, using the cut-off 1.64 or 2.665 for ΔFD as described6,7; for the Expression 
model, the rs9277534 SNP variant was predicted by DPB1 genotype8. Statistical methods are 
described in the Supplements.  
The five models displayed limited overlap, and TCE4 was the most restrictive one, as in this model 
the fewest number of pairs (36%) were classified as permissive. For the SNP models, only donor-
recipient pairs with a single unidirectional DPB1 mismatch in GvH direction could be classified, 
leaving 153/382 (40%) and 233/382 (61%) of pairs without classification according to the 
Expression or the DP2/DP5 model, respectively (Figure 1A).  
Donor-recipient pairs in the permissive/low risk or non-permissive/high risk groups according to all 
five models were comparable concerning disease- and transplant-specific characteristics 
(Supplemental Tables 2-6). In univariate analysis, we confirmed previous reports10 that DPB1 allele 
mismatches were not associated with any significant difference in OS, and this was reflected by a 
balance between significantly higher risks of aGvHD, in the presence of markedly though not 
significantly lower risks of relapse (Supplemental Table 7). Of all models, only TCE4 was 
significantly associated with superior 3-y OS and GRFS in patients transplanted from a permissive 
compared with a non-permissive donor, reflected by lower 3-y cumulative incidence (CI) of 
extensive cGvHD and NRM (Figure 1B-E). No significant associations with clinical outcomes were 
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found for the TCE3 or the ΔFD model (Supplemental Table 7). The Expression model and the 
DP2/DP5 model were both associated with a higher 100-day CI of grade≥2 aGvHD, but not with 
any of the other clinical endpoints (Supplemental Table 7). In multivariate analysis, TCE4 
permissive pairs were independently associated with superior OS and GRFS, and with lower 
hazards for NRM, cGvHD and extensive cGvHD. Moreover, compared to DPB1 allele matches, 
permissive mismatches according to all three functional models (TCE3, TCE4 and ΔFD) had 
significantly lower relapse risks (Table 2). In contrast, the high-risk mismatches according to the 
Expression model and the DP2/DP5 model were significantly associated with grade 2-4 aGvHD, 
but not with NRM or OS (Table 2). Outcome associations of all clinical co-variates used in the 
multivariate analyses are shown in Supplemental Table 8. 
Our study is the first to compare HCT outcome associations for the five major biological models of 
DPB1 permissiveness. The results show that the concordance on the predicted permissiveness of 
DPB1 mismatches among the different models is evident but far from outright, suggesting that, 
even if all models describe a common biological phenomenon (the alloreactivity of T-cells against 
incompatible DPB1 molecules), each of them may capture and emphasize only some aspects of 
this interaction. The outcome analyses confirm previous reports that functional DPB1 matching 
according to TCE is significantly associated with survival after UD-HCT2-5, while DPB1 matching 
according to the SNP tag predicts the risks of aGvHD8-9. In this context, TCE4 is the most 
restrictive but appears as the best common denominator for permissiveness/low risk in all five 
models. In particular, the survival benefit of TCE4-permissive transplants over their non-permissive 
counterparts is mainly reflected by reduced NRM and cGvHD risks, providing support to the 
hypothesis that leveraging on permissive DPB1 mismatches might be a promising way to reduce 
NRM without compromising the graft-versus-malignancy effect of allogeneic HCT. 
The study has several limitations. First, the number of pairs under analysis is relatively small, in 
particular for the two SNP tag models where DPB1 typing of up to 61% of pairs could not be 
classified. However, association of these two models with aGvHD risks is in agreement with 
previous reports from larger studies8,9. Second, an apparent difference with previous data from 
larger studies3,5 is the lack of association with TCE3. This might reflect the stem cell source, which 
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was peripheral blood in 81% of our patients while bone marrow was used in at least 50% of 
patients from the other studies3,5. Moreover, 91% of our patients received in vivo T-cell depletion 
with ATG, while this was adopted in less than 30% of patients in other studies3,5. It should also be 
noted that TCE4 has been previously found to be associated with OS, including an analysis of non-
overlapping GITMO transplants from earlier years4, a recent study from the French Registry11, and 
a large multicentre study from the International Histocompatibility Workshop3. Since the latter did 
not show a significant advantage of TCE4 over TCE3, and DPB1 permissive donors are more 
frequent in TCE3, TCE3 was adopted by stem cell donor registries and not further investigated in 
subsequent studies5. The greater restrictiveness of TCE4 compared to TCE3 in assigning 
permissiveness is due to appreciation of DPB1*02 as a separate functional group. Interestingly, 
HLA-DP2 is the so far only HLA-DP specificity associated with autoimmunity12, and recent 
evidence suggests a similar breadth of the alloreactive T cell receptor repertoire in permissive pairs 
involving this allele group compared to non-permissive pairs13, arguing in favor of a functional basis 
for TCE4. 
In conclusion, our results highlight the relevance of refining transplant-associated risks according 
to the biological significance of HLA matching. In particular, they confirm the association between 
the SNP tag models and aGvHD, while TCE4 should be prioritized for its highest performance in 
predicting survival and non-relapse related events. Moreover, since most of TCE4 permissive 
donors are classified as low-risk for both SNP tag models, they may be the best alternative to favor 
positive overall outcomes. Clearly, additional and possibly prospective studies should be 
performed to provide more definitive evidence for the respective value of the five DPB1 models, 
also in view of emerging new strategies for GvHD prophylaxis, which could modulate the observed 
outcome associations.
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Table 1. Patient, transplant and donor characteristics. 
 Population n= 422 
Median follow-up for survivors, years (range) 3.2 (0.1-6) 
Patient age, years, median (range) 49 (18-70) 
Patient gender, male, n (%) 244 (58%) 
Type of diagnosis, n (%)  
AML 168 (40%) 
ALL 63 (15%) 
MDS or MPN 69 (16%) 
Lymphoma and Myeloma 110 (26%) 
CLL 12 (3%) 
Disease status according to EBMT risk14, n (%)  
Early 191 (45%) 
Intermediate 111 (26%) 
Advanced 120 (29%) 
HCT-CI score15, median (range) 1 (0-7) 
Karnofsky performance status, median (range) 90% (50-100) 
Donor gender, male, n (%) 306 (72%) 
N° of previous pregnancies for female donors, median (range) 0 (0-6 
Female donor/male recipient, n (%) 61 (14%) 
Host/donor CMV serostatus, n(%)  
Pos/pos 157 (37%) 
Pos/neg 166 (39%) 
Neg/pos 36 (9%) 
Neg/neg 53 (13%) 
Missing 10 (2%) 
Type of conditioning, n (%)  
MAC 271 (64%) 
RIC 111 (35%) 
Source of stem cells, n (%)  
PB 343 (81%) 
BM 79 (19%) 
ATG-based GvHD prophylaxis, n (%) 382 (91%) 
GvHD prophylaxis details:  
ATG+CSA+MTX  341 (81%) 
ATG+Sirolimus+MMF 26 (6%) 
Other ATG-based prophylaxis 15 (4%) 
CSA+MTX 24 (5%) 
Other prophylaxis 16 (4%) 
 
Abbreviations: AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; MDS, 
myelodysplastic syndromes; MPN, myeloproliferative neoplasms; CLL, chronic lymphocytic 
leukemia; CMV, Cytomegalovirus; MAC, myeloablative conditioning; RIC, reduced intensity 
conditioning; PB, peripheral blood; BM, bone marrow; ATG, anti-T-lymphocytic globulin; CSA, 
Cyclosporine A; MTX, Methotrexate. 
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Table 2. Multivariate analysis of DPB1 mismatch models and association with HCT outcomes. 
 OS GRFS Relapse NRM aGvHD≥2 aGvHD≥3 cGvHD Ext cGvHD 
 HR (95% CI)       p HR (95% CI)    p HR (95% CI)   p HR (95% CI)   p HR (95% CI)     p HR (95% CI)   p HR (95% CI)  p HR (95% CI)   p 
TCE41: NP vs P 
           Matched vs P 
1.7 (1.1-2.4) 0.008 
2.1 (1.2-3.7) 0.01 
1.4 (1.1-1.9) 0.01 
1.5 (0.9-2.4) 0.09 
1.1 (0.7-1.7) 0.7 
2 (1.1-3.7)   0.03 
1.9 (1.1-3.2)  0.01 
2 (0.9-4.8) 0.09 
1.3 (0.8-2.1)  0.2 
Not applicable6 
1.5 (0.7-3.2) 0.3 
Not applicable6 
1.7 (1.1-2.6) 0.02 
0.8 (0.3-2)    0.6 
3.6 (1.4-9.5) 0.01 
0.9 (0.1-7.5)  0.9 
 
        
TCE32: NP vs P 
           Matched vs P 
1.1 (0.8-1.6)  0.5 
1.6 (0.9-2.7) 0.09 
1.1 (0.8-1.4)   0.5 
1.2 (0.8-1.9)   0.3 
1 (0.6-1.5)  0.9 
1.9 (1.1-3.4) 0.04 
1.1 (0.7-1.8)   0.6 
1.4 (0.6-3)      0.4 
1.2 (0.8-1.9)  0.4 
Not applicable6 
1.4 (0.6-2.9)  0.4 
Not applicable6 
1.2 (0.8-1.8)  0.4 
0.6 (0.2-1.5)  0.3 
1.7 (0.8-3.6)  0.1 
0.5 (0.1-3.6)  0.5 
 
        
ΔFD3: NP vs P 
         Matched vs P 
1 (0.7-1.5)     0.8 
1.5 (0.9-2.5)   0.1 
1 (0.7-1.4)    0.9 
1.2 (0.8-1.9)  0.4 
1.3 (0.8-2)    0.3 
2 (1.1-3.6)    0.02 
0.9 (0.5-1.5)  0.7 
1.3 (0.6-2.7)   0.5 
0.9 (0.5-1.4)   0.6 
Not applicable6 
0.8 (0.4-1.9)  0.6 
Not applicable6 
1 (0.7-1.6)   0.9 
0.6 (0.2-1.4) 0.2 
0.9 (0.4-2.1)  0.9 
0.3 (0.1-2.5)  0.3 
 
        
Expression4: high vs low risk 
               Matched vs low risk 
1 (0.6-1.6)     0.9 
1.6 (0.9-2.8)  0.08 
0.8 (0.5-1.2)  0.2 
1.1 (0.7-1.7)  0.7 
0.6 (0.3-1.1)  0.1 
1.4 (0.7-2.5)  0.3 
1.1 (0.6-2.2)  0.7 
1.5 (0.7-3.4)  0.3 
2.2 (1.1-4.2)  0.02 
Not applicable6 
1.9 (0.6-6.2) 0.3 
Not applicable6 
1.2 (0.7-2.2)  0.4 
0.7 (0.3-1.7)  0.4 
1.7 (0.6-4.5)   0.3 
0.5 (0.1-3.7)   0.3 
 
        
DP2/DP55: high vs low risk 
               Matched vs low risk 
1.2 (0.5-2.5)  0.7 
1.8 (1-3.2)   0.05 
0.8 (0.5-1.6)  0.6 
1 (0.6-1.7)    0.9 
0.9 (0.4-2.2)  0.8 
1.6 (0.8-3.2)  0.2 
1.3 (0.5-3.7)  0.6 
1.5 (0.6-3.7)  0.3 
3.8 (1.5-9.6) 0.006 
Not applicable6 
6.9 (1.5-31) 0.01 
Not applicable6 
1.1 (0.4-3.1)  0.8 
0.5 (0.2-1.5)  0.2 
4.1 (1-17)    0.05 
0.6 (0.1-4.7)  0.6 
 
1TCE4 NP, P and matched: N= 247, 135 and 40, respectively. 
2TCE3 NP, P and matched: N= 174, 208 and 40, respectively. 
3DFD NP, P and matched: N= 123, 259 and 40, respectively; cut-off 2.665. 
4Expression high risk, low risk and matched: N= 76, 153 and 40, respectively. 
5DP2/DP5 high risk, low risk and matched: N= 31, 118 and 40, respectively. 
6Not applicable since no cases of aGvHD occurred in the DPB1 matched cohort. 
Abbreviations are defined in the text. Co-variates in the multivariate models included patient age, disease phase, HCT-CI, female donor to male 
recipient, host-donor CMV serostatus, conditioning intensity, stem cell source, ATG use, HLA-matching on 5 loci, center effect.  
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FIGURE LEGEND 
Figure 1. Comparative stratification of donor-recipient pairs according to five different 
biological models of DPB1 permissiveness, and outcome associations for TCE4.  A) 
Classification of the 382 DPB1 mismatched pairs under analysis in this study, as permissive or low 
risk (green) or as non-permissive or high risk (red) group according to five different biological 
models of permissiveness, as described in the text. For the Expression and the DP2/DP5 model, 
only pairs with single mismatches in the GvH direction can be stratified, the others cannot be 
classified (grey). The model under investigation, and the relevant numbers in each category 
(green, red or grey) are indicated to the left and to the right of the panel, respectively.  The bottom 
panels show Kaplan-Meier probabilities for OS (B), GRFS (C), and CI of NRM (D) and extensive 
cGvHD (E) stratified for functional DPB1 matching according to TCE4 model, with permissive and 
non-permissive groups represented by the red and black curves, respectively. 
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Clinical endpoints definitions and statistical methods. 
Acute GvHD (aGvHD) and chronic GvHD (cGvHD) were defined and scored according to the 
Glucksberg and Seattle criteria, respectively1-2. NRM was defined as death from any cause while in 
continuous remission of the primary disease. OS was defined as the interval from HSCT to death 
from any cause. GRFS events were defined as grade 3–4 acute GVHD, extensive chronic GVHD, 
disease relapse, or death from any cause after HSCT3. Actuarial probabilities were determined at 3 
years. Baseline characteristics among groups were compared using the Chi-square test for 
categorical variables, while the distribution of continuous variables was compared using the Mann-
Whitney U test. The probabilities of OS and GRFS were estimated using the Kaplan-Meyer 
estimator and groups were compared by the log-rank test4-5. Cumulative incidences (CI) were 
estimated for GvHD, NRM and relapse to accommodate competing risks, and tests of equality 
across groups were performed according to Gray6-7. Relapse was a competing risk for NRM, death 
from any cause was a competing risk for relapse. Both relapse and death from any causes were 
competing risks for GvHD. Multivariate analysis were built to test the independent prognostic value 
of DPB1 mismatch permissiveness: each DPB1 mismatch model was the main effect term and was 
held in all steps of model building. Cox proportional hazard models were adopted for OS and 
GRFS8, while Fine-Gray proportional hazard regression models for competing events were 
adopted for aGvHD, cGvHD, relapse and NRM. Covariates included: patient age, disease phase, 
HCT-CI, female donor to male recipient, host-donor CMV serostatus, conditioning intensity, stem 
cell source, ATG use, HLA-matching on 5 loci (HLA-A, -B, -C, -DRB1 and –DQB1), center effect 
(>10 HSCT performed each year Vs ≤10). Interactions between each covariate and each DPB1 
mismatch model were tested and not found. In particular, no interaction was found between HLA 
matching on 5 loci and each model. The proportional hazard assumption was met for all variables. 
The type I error was fixed at 0.05. Statistical analyses were performed with R version 3.3.3 (R 
Development Core Team, Vienna, Austria).  
1. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft versus host disease in 
human recipients of marrow from HLA matched sibling donors. Transplantation. 1974 
Oct;18(4):295-304.  
2. Lee SJ, Vogelsang G, Flowers ME. Chronic graft versus host disease. Biol Blood Marrow 
Transplant. 2003 Apr;9(4):215-33. 
3. Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free 
survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. 
Bone Marrow Transplant. 2016;51(4):610–611.  
4. Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. J Am Stat 
Assoc. 1958;53:457–481.  
5. Mantel N. Evaluation of survival data and two new rank order statistics arising in its 
consideration. Cancer Chemother Rep. 1966;50(3):163–170.  
6. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the 
presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695–
706.  
7. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing 
risk. Ann Stat. 1988;16:1141–1154.  
8. Cox DR. Regression Models and Life-Tables. Journal of the Royal Statistical Society. 
Series B (Methodological). 1972;34(2):187–220. 
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Supplemental Table 1a. Patient, donor and transplant characteristics in DPB1 typed or non-typed 
cases. 
 
 
 
 
Non-DPB1 typed 
(N=582) 
DPB1 typed 
(N=422) 
p 
Median follow-up for survivors, years (range) 3.1 (0.3-6.1) 3.2 (0.3-6.2) 0.7 
HSCT year, median (range) 2014 (2012-2015) 2013 (2012-2015) 0.001 
Patient age, years, median (range) 51 (18-69) 49 (18-71) 0.003 
Patient gender, male, n  345 245 0.7 
Type of diagnosis, n    0.2 
AML or ALL 308 232  
MDS or MPN 127 69  
Lymphoma or Myeloma 138 109  
CLL 9 12  
Disease status at HSCT, n    0.3 
Early 293 191  
Intermediate 135 114  
Advanced 145 105  
HCT-CI score, median (range) 1 (0-7) 1 (0-7) 0.1 
Karnofsky PS, median (range) 90% (40-100) 90% (50-100) 0.4 
Donor age, years, median (range) 28 (18-57) 29 (18-57) 0.6 
Donor gender, male, n  415 306 0.7 
Female donor/male recipient, n  97 61 0.3 
Host/donor CMV serostatus, n   0.3 
Pos/pos 206 156  
Pos/neg 266 167  
Neg/pos 38 36  
Neg/neg 72 53  
Type of conditioning, n    0.3 
MAC 390 296  
RIC 192 126  
Source of stem cells, n    0.1 
PB 492 342  
BM 90 80  
ATG-based GvHD prophylaxis, n  476 350 0.6 
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Supplemental Table 1b. Univariate analysis for transplant outcomes in DPB1 typed or non-typed cases.1  
 3-y OS 3-y GRFS 3-y 
Relapse 
3-y NRM 100-d 
aGvHD≥2 
100-d 
aGvHD≥3 
3-y 
cGvHD 
3-y ext 
cGvHD 
DPB1 typing         
DPB1 typed (n=422) 52 (46-56) 32 (27-36) 30 (25-35) 27 (23-31) 21 (17-25) 7 (5-10) 28 (24-32) 9 (6-12) 
Non-DPB1 typed (N=582) 56 (52-61) 35 (31-39) 34 (30-38) 23 (20-29) 22 (18-25) 7 (5-10) 27 (23-30) 9 (6-11) 
p 0.15 0.45 0.08 0.08 0.60 0.85 0.68 0.80 
 
1shown are mean percentages (range in parenthesis) for each outcome. 
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Supplemental Table 2. Patient, donor and transplant characteristics in permissive and non 
permissive DPB1 mismatched pairs according to the TCE3 model 
  
 Permissive (N=208) Non-permissive (N=174) p 
Median follow-up for survivors, years (range) 3.4 (0.3-6) 3.1 (0.3-6) 0.28 
HSCT year, median (range) 2013 (2012-2015) 2013 (2012-2015) 0.12 
Patient age, years, median (range) 48 (18-71) 50 (19-66) 0.49 
Patient gender, male, n  101 117 0.72 
Type of diagnosis, n   0.16 
AML or ALL 121 85  
MDS or MPN 35 32  
Lymphoma and Myeloma 52 57  
Disease status at HSCT, n    0.43 
Early 100 74  
Intermediate 54 45  
Advanced 54 55  
HCT-CI score, median (range) 0 (0-7) 1 (0-5) 0.97 
Karnofsky PS, median (range)   0.39 
Donor age, years, median (range) 27 (19-55) 30 (20-56) 0.23 
Donor gender, male, n  149 126 0.87 
Female donor/male recipient, n  28 29 0.38 
Host/donor CMV serostatus, n  90% (60-100) 90% (50-100) 0.35 
Pos/pos 71 71  
Pos/neg 81 71  
Neg/pos 19 11  
Neg/neg 31 19  
Type of conditioning, n   0.58 
MAC 150 121  
RIC 58 53  
Source of stem cells, n   0.01 
PB 179 132  
BM 29 42  
ATG-based GvHD prophylaxis, n 189 156 0.69 
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Supplemental Table 3. Patient, donor and transplant characteristics in in permissive and non 
permissive DPB1 mismatched pairs according to the TCE4 model 
 
  
 Permissive (N=135) Non-permissive (N=247) p 
Median follow-up for survivors, years (range) 3.4 (0.3-6) 3.3 (0.3-6) 0.17 
HSCT year, median (range) 2014 (2012-2015) 2013 (2012-2015) 0.45 
Patient age, years, median (range) 48 (18-68) 49 (19-71) 0.46 
Patient gender, male, n  80 138 0.52 
Type of diagnosis, n    0.86 
AML or ALL 75 131  
MDS or MPN 22 45  
Lymphoma or Myeloma 38 71  
Disease status at HSCT, n    0.80 
Early 62 112  
Intermediate 37 62  
Advanced 36 73  
HCT-CI score, median (range) 0 (0-7) 1 (0-5) 0.96 
Karnofsky PS, median (range) 90% (70-100) 90% (50-100) 0.77 
Donor age, years, median (range) 29 (19-55) 28 (19-56) 0.68 
Donor gender, male, n  94 181 0.45 
Female donor/male recipient, n  23 34 0.39 
Host/donor CMV serostatus, n   0.35 
Pos/pos 50 92  
Pos/neg 51 101  
Neg/pos 15 15  
Neg/neg 16 34  
Type of conditioning, n    0.86 
MAC 95 176  
RIC 40 71  
Source of stem cells, n   0.03 
PB 118 193  
BM 17 54  
ATG-based GvHD prophylaxis, n  127 230 0.13 
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Supplemental Table 4. Patient, donor and transplant characteristics in in permissive and non-
permissive DPB1 mismatched pairs according to the ΔFD model1 
 
1shown are data for cut-off 2.665; data for cut-off 1.64 were not significantly different. 
 
  
 <2.665 (N=259) ≥2.665 (N=123) p 
Median follow-up for survivors, years (range) 3.5 (0.3-6) 2.9 (0.3-5) 0.12 
HSCT year, median (range) 2013 (2012-2015) 2014 (2012-2015) 0.97 
Patient age, years, median (range) 48 (18-71) 52 (19-66) 0.48 
Patient gender, male, n  155 63 0.11 
Type of diagnosis, n    0.59 
AML or ALL 144 62  
MDS or MPN 45 22  
Lymphoma or Myeloma 70 39  
Disease status at HSCT, n    0.78 
Early 120 54  
Intermediate 68 31  
Advanced 71 38  
HCT-CI score, median (range) 0 (0-7) 1 (0-6) 0.38 
Karnofsky PS, median (range) 90% (60-100) 90% (50-100) 0.25 
Donor age, years, median (range) 28 (19-56) 30 (20-52) 0.98 
Donor gender, male, n  184 91 0.55 
Female donor/male recipient, n  40 17 0.68 
Host/donor CMV serostatus, n   0.60 
Pos/pos 93 49  
Pos/neg 105 47  
Neg/pos 23 7  
Neg/neg 32 18  
Type of conditioning, n    0.59 
MAC 186 85  
RIC 73 38  
Source of stem cells, n    0.15 
PB 216 95  
BM 43 28  
ATG-based GvHD prophylaxis, n  233 112 0.74 
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Supplemental Table 5. Patient, donor and transplant characteristics in in low risk and high risk 
DPB1 mismatched pairs according to the Expression model  
 
  
 Low risk (N=153) High risk (N=76) p 
Median follow-up for survivors, years (range) 3.5 (0.3-6) 3.3 (0.3-6) 0.59 
HSCT year, median (range) 2013 (2012-2015) 2013 (2012-2015) 0.31 
Patient age, years, median (range) 49 (18-71) 49 (19-68) 0.98 
Patient gender, male, n  93 45 0.82 
Type of diagnosis, n    0.68 
AML or ALL 80 44  
MDS or MPN 27 13  
Lymphoma or Myeloma 46 19  
Disease status at HSCT, n    0.94 
Early 71 37  
Intermediate 39 19  
Advanced 43 20  
HCT-CI score, median (range) 1 (0-6) 0 (0-7) 0.26 
Karnofsky PS, median (range) 90% (50-100) 90% (70-100) 0.49 
Donor age, years, median (range) 28 (19-56) 29 (19-54) 0.19 
Donor gender, male, n  105 53 0.86 
Female donor/male recipient, n  28 12 0.64 
Host/donor CMV serostatus, n   0.47 
Pos/pos 62 24  
Pos/neg 53 33  
Neg/pos 13 5  
Neg/neg 21 12  
Type of conditioning, n    0.73 
MAC 112 54  
RIC 41 22  
Source of stem cells, n    0.09 
PB 129 57  
BM 24 19  
ATG-based GvHD prophylaxis, n  136 72 0.15 
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Supplemental Table 6. Patient, donor and transplant characteristics in low risk or high risk DPB1 
mismatched pairs according to the DP2/DP5 model 
 
 
  
 DP2 (N=118) DP5 (N=31) p 
Median follow-up for survivors, years (range) 3.4 (0.3-6.2) 2.8 (0.3-6.1) 0.39 
HSCT year, median (range) 2013 (2012-2015) 2013 (2012-2015) 0.74 
Patient age, years, median (range) 49 (18-69) 45 (19-66) 0.16 
Patient gender, male, n  74 20 0.85 
Type of diagnosis, n    0.67 
AML or ALL 58 18  
MDS or MPN 22 5  
Lymphoma or Myeloma 38 8  
Disease status at HSCT, n    0.83 
Early 57 14  
Intermediate 28 9  
Advanced 33 8  
HCT-CI score, median (range) 1 (0-6) 1 (0-5) 0.58 
Karnofsky PS, median (range) 90% (50-100) 90% (70-100) 0.98 
Donor age, years, median (range) 28 (19-56) 29 (23-54) 0.09 
Donor gender, male, n  84 22 0.98 
Female donor/male recipient, n  20 4 0.41 
Host/donor CMV serostatus, n   0.35 
Pos/pos 48 8  
Pos/neg 37 14  
Neg/pos 11 2  
Neg/neg 18 6  
Type of conditioning, n    0.07 
MAC 91 19  
RIC 27 12  
Source of stem cells, n    0.39 
PB 96 24  
BM 22 7  
ATG-based GvHD prophylaxis, n  104 29 0.39 
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Supplemental Table 7. Univariate analysis for transplant outcomes and different models of DPB1 mismatch permissivity.1 
 3-y OS 3-y GRFS 3-y 
Relapse 
3-y NRM 100-d 
aGvHD≥2 
100-d 
aGvHD≥3 
3-y 
cGvHD 
3-y ext 
cGvHD 
DPB1 allele matching status         
Matched (n=40) 43 (26-59) 34 (20-49) 38 (23-54) 26 (13-40) 0 0 18 (8-31) 5 (1-16) 
Mismatched (n=382) 53 (47-58) 32 (27-37) 29 (24-34) 27 (22-31) 23 (19-27) 8 (6-11) 29 (24-33) 9 (7-13) 
p 0.81 0.68 0.16 0.81 <0.01 0.05 0.10 0.35 
TCE3         
Permissive mismatch (n= 208) 53 (46-60) 33 (26-40) 30 (24-37) 26 (20-32) 22 (16-28) 7 (4-11) 27 (21-33) 6 (4-10) 
Non Permissive mismatch (n=174) 52 (44-60) 30 (23-38) 27 (20-34) 28 (21-35) 24 (18-31) 9 (6-14) 31 (24-38) 13 (8-19) 
p 0.50 0.35 0.64 0.43 0.48 0.57 0.31 0.03 
TCE4         
Permissive mismatch (n=135) 60 (51-68) 36 (28-45) 30 (22-38) 21 (15-29) 21 (15-29) 7 (3-12) 26 (19-34) 4 (2-9) 
Non Permissive mismatch (n=247) 49 (42-55) 29 (24-35) 28 (22-34) 30 (24-36) 24 (19-29) 9 (5-12) 30 (25-37) 12 (8-17) 
p 0.05 0.04 0.96 0.09 0.56 0.58 0.3 0.01 
ΔFD         
<2.65 (n=259) 54 (47-60) 31 (26-38) 28 (23-34) 27 (22-33) 23 (18-28) 8 (5-12) 28 (23-34) 9 (6-13) 
≥2.65 (n=123) 51 (41-60) 32 (24-41) 30 (22-39) 25 (18-33) 23 (16-31) 7 (4-13) 29 (21-38) 10 (6-17) 
p 0.83 0.71 0.57 0.71 0.90 0.65 0.88 0.75 
Expression model         
low risk (n=153) 56 (47-63) 27 (20-35) 34 (26-42) 23 (17-30) 16 (10-22) 5 (2-9) 29 (22-36) 9 (5-14) 
high risk (n=76)  57 (45-68) 39 (28-50) 23 (14-34) 26 (16-36) 32 (22-43) 9 (4-17) 34 (24-45) 12 (6-20) 
p 0.95 0.23 0.23 0.81 <0.01 0.32 0.30 0.42 
DP2/DP5 model         
low risk (n=118) 59 (49-67) 29 (21-38) 27 (19-36) 25 (17-33) 15 (9-22) 4 (2-9) 32 (24-41) 11 (6-17) 
high risk (n=31)  62 (42-77) 39 (21-56) 31 (15-49) 23 (10-40) 43 (25-60) 20 (8-36) 26 (12-42) 16 (6-31) 
p 0.76 0.47 0.62 0.80 0.001 0.01 0.67 0.32 
 
1shown are mean percentages (range in parenthesis) for each outcome. 
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Supplemental Table 8. Multivariate analysis of clinical factors associated with HCT outcomes. 
 OS GRFS Relapse NRM aGvHD≥2 aGvHD≥3 cGvHD Ext cGvHD 
 HR (95% CI)       p HR (95% CI)    p HR (95% CI)   p HR (95% CI)   p HR (95% CI)    p HR (95% CI)   p HR (95% CI)  p HR (95% CI)   p 
TCE41: NP Vs P 
            Matched Vs P 
1.7 (1.1-2.4) 0.008 
2.1 (1.2-3.7) 0.01 
1.4 (1.1-1.9) 0.01 
1.5 (0.9-2.4) 0.09 
1.1 (0.7-1.7) 0.7 
2 (1.1-3.7)   0.03 
1.9 (1.1-3.2)  0.01 
2 (0.9-4.8) 0.09 
1.3 (0.8-2.1)  0.2 
Not applicable2 
1.5 (0.7-3.2) 0.3 
Not applicable2 
1.7 (1.1-2.6) 0.02 
0.8 (0.3-2)    0.6 
3.6 (1.4-9.5) 0.01 
0.9 (0.1-7.5)  0.9 
Disease status: Intermediate Vs Early 
                           Advanced Vs early 
1.4 (0.9-2.1) 0.09 
2.3 (1.6-3.3) <10-3 
1.3 (0.9-1.8)  0.1 
1.5 (1.1-2)   0.01 
1.5 (0.9-2.5)  0.09 
2 (1.2-3.2)  0.005 
1.6 (0.9-2.7) 0.09 
1.9 (1.2-3.3) 0.01 
1.1 (0.6-1.9)  0.7 
0.7 (0.4-1.3)  0.3 
0.7 (0.3-1.7)  0.4 
0.6 (0.2-1.6)  0.3 
1.1 (0.7-1.8)   0.6 
1 (0.6-1.7)     0.9 
2.4 (0.9-5.5) 0.09 
1.2 (0.4-3.2)   0.7 
Patient age 1 (0.9-1.1)    0.2 1 (0.9-1.1)   0.2 1 (0.9-1.1)    0.3 1 (0.9-1.1)    0.2 1 (0.9-1.1)    0.4 1 (0.9-1.1)     0.9 1 (0.9-1.1)     0.1 1 (0.9-1.1)     0.9 
HCTI-Score: ≥1 Vs 0 1.3 (0.9-1.9)  0.09 1.4 (1.1-1.9) 0.008 1.1 (0.7-1.6)  0.7 1.6 (1.1-2.5)  0.04 1.2 (0.7-1.9)  0.5 1.5 (0.7-3.1)  0.3 2.2 (1.4-3.4) <10-3 2.2 (1-5)        0.05 
Female donor to male recipient 1.1 (0.7-1.8)  0.6 1.3 (0.9-1.1) 0.2 1.1 (0.6-2.1)  0.6 1.1 (0.6-2)   0.8 0.6 (0.3-1.3)  0.2 0.8 (0.3-2.3)  0.6 1.2 (0.7-2.1)  0.4 2.4 (1.1-5.4)  0.04 
CMV status: neg/neg Vs other 0.7 (0.4-1.2)  0.2 0.9 (0.6-1.4) 0.7 0.6 (0.3-1.3)  0.2 0.8 (0.4-1.7)  0.6 1.1 (0.5-2.1)  0.9 1.3 (0.5-3.6)  0.6 1 (0.5-2)       0.9 1 (0.4-2.8)     0.9 
Conditioning: MAC Vs RIC 1.3 (0.9-1.9)  0.1 1.1 (0.8-1.5) 0.5 1 (0.6-1.6)    0.9 1.3 (0.8-2.1)  0.4 1.4 (0.8-2.4)  0.2 1.9 (0.7-5.1)  0.2 1.1 (0.7-1.7)   0.8 0.5 (0.2-1.1)  0.08 
Stem cell source: PB Vs BM 1.1 (0.7-1.6)  0.8 1.1 (0.8-1.6)  0.6 1 (0.6-1.7)    0.9 1.1 (0.6-1.9)  0.8 1.4 (0.7-2.7) 0.3 2.4 (0.7-8.4)  0.2 0.8 (0.4-1.3)  0.3 0.6 (0.2-1.7)   0.4 
ATG use  1.2 (0.5-2.7)  0.7 0.9 (0.5-1.7)  0.8 2.6 (0.6-11)   0.2 1 (0.3-2.8)    0.9 0.5 (0.2-1.4)  0.2 0.4 (0.1-1.4)  0.1 1 (0.4-2.4)     0.9 0.9 (0.2-3.2)  0.8 
Overall HLA-matching: 9/10 Vs 10/10 1.8 (1-3.3)   0.06 1.1 (0.7-1.7)  0.6 2 (0.9-4.2)   0.07 1.5 (0.7-3.3)  0.3 1.4 (0.6-3)    0.5 1.2 (0.4-4.1)  0.8 0.8 (0.4-1.4)  0.4 1.5 (0.3-6.6)  0.6 
Center effect: ≥10 HCT/year Vs <10 0.9 (0.7-1.3)  0.7 1 (0.7-1.3)    0.8 0.8 (0.5-1.3) 0.4 0.9 (0.5-1.4)  0.6 0.9 (0.6-1.6)  0.9 0.7 (0.3-1.5)  0.3 1.1 (0.7-1.7)  0.7 1.9 (0.8-4.6)  0.2 
 
1TCE4 NP, P and matched: N= 247, 135 and 40, respectively. 
2Not applicable since no cases of aGvHD occurred in the DPB1 matched cohort. 
Shown are the data for the TCE4 functional model as main effect term and covariates as described in Statistical methods. 
 
